Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections
Giuseppe Pipitone1, Stefano Di Bella2, Alberto Enrico Maraolo3
1Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90127 Palermo, Italy.
Abstract:
Human Pseudomonas infections have high morbidity and mortality rates. Pseudomonas bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas is herein reviewed and discussed.
Insights
Intravenous fosfomycin shows promise for treating difficult Pseudomonas infections. Its favorable properties and synergistic effects offer a new therapeutic option for multidrug-resistant bacteria.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- * Pseudomonas infections lead to high rates of illness and death.
- * These bacteria can cause sepsis and exhibit multidrug resistance.
- * Treating Pseudomonas infections is challenging due to complex clinical, microbiological, and pharmacological factors.
Purpose of the Study:
- * To review current literature on intravenous fosfomycin for Pseudomonas infections.
- * To discuss its epidemiological, microbiological, and clinical data.
- * To evaluate its potential as a repurposed antimicrobial therapy.
Main Methods:
- * Comprehensive literature review of studies on intravenous fosfomycin.
- * Analysis of pharmacokinetic/pharmacodynamic properties.
- * Evaluation of antibiofilm activity and synergistic effects.
Main Results:
- * Intravenous fosfomycin demonstrates favorable pharmacokinetic/pharmacodynamic profiles for various infections.
- * It possesses significant antibiofilm activity.
- * It exhibits synergistic effects when combined with other antimicrobials.
Conclusions:
- * Intravenous fosfomycin is a promising therapeutic option for Pseudomonas infections.
- * Its repurposing in combination therapy warrants further investigation.
- * It offers a potential solution for multidrug-resistant Pseudomonas strains.
More Related Videos
11:20Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...